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Intrahepatic malignant tumours include hepatocellular carci-
nomas (HCC), cholangiocarcinomas (CC) and combined hepa-
tocholangiocarcinomas (cHCC-CC), a group of rare and poorly 
characterized tumours that exhibit both biliary and hepatocytic 
differentiation. The aim of the study was to characterize the 
molecular pathways specifically associated with cHCC-CC patho-
genesis. We performed a genome-wide transcriptional analysis 
of 20 histologically defined cHCC-CC and compared them with 
a series of typical HCC and of CC. Data were analysed by gene 
set enrichment and integrative genomics and results were further 
validated in situ by tissue microarray using an independent series 
of 152 tumours. We report that cHCC-CC exhibit stem/progeni-
tor features, a down-regulation of the hepatocyte differentiation 
program and a commitment to the biliary lineage. TGFβ and Wnt/
β-catenin were identified as the two major signalling pathways 
activated in cHCC-CC. A β-catenin signature distinct from that 
observed in well-differentiated HCC with mutant β-catenin was 
found in cHCC-CC. This signature was associated with microen-
vironment remodelling and TGFβ activation. Furthermore, inte-
grative genomics revealed that cHCC-CC share characteristics of 
poorly differentiated HCC with stem cell traits and poor progno-
sis. The common traits displayed by CC, cHCC-CC and some HCC 
suggest that these tumours could originate from stem/progenitor 
cell(s) and raised the hypothesis of a potential continuum between 
intrahepatic CC, cHCC-CC and poorly differentiated HCC.
Introduction
Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) 
are the two major types of primary liver cancers. More than 80% of 
primary liver cancers are HCC usually occurring in fibrotic and cir-
rhotic livers related to chronic viral infections, metabolic disorders, 
high alcohol intake or hemochromatosis (1). CC, which account for 
about 15% of primary liver cancers, derive either from small intrahe-
patic bile ducts or ductules (intrahepatic cholangiocarcinoma, ICC), 
or from large hilar or extrahepatic bile ducts (extrahepatic cholan-
giocarcinoma, ECC (1)). Another rare and aggressive subtype of pri-
mary liver cancer has been defined according to the World Health 
Organization criteria, referred to as combined hepatocholangiocarci-
noma (cHCC-CC), sharing clinicopathological features of both HCC 
and ICC, and can arise in both non-cirrhotic and cirrhotic livers (2–5). 
Besides the classical cHCC-CC, which contain areas of typical HCC 
and CC, three subtypes with stem cell features were defined, one of 
them called cholangiolocellular carcinoma (3). The tumoural cells of 
these particular subtypes show intermediate features between hepato-
cytes and cholangiocytes. Today, the diagnosis of cHCC-CC and their 
different subtypes relies on histopathological analyses and unified cri-
teria, including molecular markers, are still pending.
Genomic approaches have been successful in identifying genes and 
pathways involved in the pathogenesis of CC and HCC. Recently, by 
gene expression profiling of a large cohort of HCC and a small ser-
ies of CC and cHCC-CC, Woo et  al. identified a subtype of HCC 
with CC-like traits associated with a poor prognosis (6), thus suggest-
ing a phenotypic overlap between HCC, CC and cHCC-CC. In the 
present work, we profiled a series of 20 histologically well-defined 
cHCC-CC and a series of typical HCC and ICC. Functional ana-
lysis, cross-comparison with published datasets and in situ validation 
using an independent set of tumours showed that cHCC-CC displayed 
stem/progenitor features, a down-regulation of an HNF4-driven hep-
atocyte differentiation program and a commitment to the biliary lin-
eage. Wnt/β-catenin and TGFβ were the main signaling pathways 
activated in cHCC-CC. Importantly, the Wnt/β-catenin signature in 
cHCC-CC differed dramatically from that in well-differentiated HCC 
with mutant β-catenin. Finally, integrative genomics revealed that 
cHCC-CC recapitulated a subset of HCC, which exhibits progenitor 
features and poor prognosis.
Materials and methods
Patients and histopathological variables
Two different series of surgically resected primary liver tumours (Cochin 
Hospital, Paris, France) were used in this study. Series #1 included 20 cHCC-
CC, 3 ICC, 7 typical HCC (Table I), which were profiled by microarray. 
Since we showed that HCC with mutant β-catenin were well-differentiated 
tumours with specific morphologic and metabolic features (7), we discarded 
them and selected Edmondson-Steiner grade 3 HCC (8) with macrotrabecular 
morphology. Epithelial cell adhesion molecule (EpCAM) being a marker of 
HCC with stem/progenitor features (9), we selected half of them with posi-
tivity for EpCAM. The β-catenin status of the 20 cHCC-CC and ICC were 
all of WT genotype. Series #2 included an independent validation set of 48 
cHCC-CC, 54 ICC and 152 HCC (among them 60 with mutant β-catenin (7)). 
The use of clinical and pathologic records was in agreement with French laws 
and ethical guidelines related to the protection of the patient. Hematoxylin 
and eosin-stained sections were histologically assessed by two of the authors 
(B.T. and P-A. J.). Hepatic fibrosis in non-cancerous livers was graded accord-
ing to the METAVIR classification (10).
Tissue microarray
Core tissue biopsies were taken from individual paraffin-embedded tumours 
and arranged in recipient tissue array-blocks using a microarrayer (Beecher 
Instruments, Woodland, CA, USA). Three cores of 0.8 mm in diameter were 
sampled from each tumour.
Immunohistochemistry
Paraffin sections were processed as described previously (7). 
Immunohistochemistry was done on standard (series 1) and tissue microarray 
slides (series 2) using antibodies against β-catenin, EpCAM, GLUL, KRT19, 
LEF1 and SOX9 (supplementary materials and methods).
In situ hybridisation
The PCR template coding for almost the full-length human albumin (ALB) 
was generated from the MGC clone containing the complete cDNA for the 
human protein (IMAGE ID: 4734617) purchased from Invitrogen (Invitrogen, 
Carlsbad, USA). Detailed protocol is given as supplementary materials and 
methods.
RNA extraction and gene expression profiling
Total RNA was isolated with TRIzol (Invitrogen, Carlsbad, USA) and quality 
controlled on Agilent’s 2100 Bioanalyzer (RNA integrity number was above 
8). Detailed protocol for GeneChip® human Gene (Affymetrix) hybridization 
is given as supplementary methods. MIAME compliant microarray data are 
available in Gene Expression Omnibus (GEO) database (GSE35306).
Abbreviations: CC, cholangiocarcinoma; cHCC-CC, combined hepatochol-
angiocarcinoma; HCC, hepatocellular carcinoma.
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Statistical analysis and data mining
Briefly, differentially expressed genes were identified by a univariate 
two-sample t-test with a random variance model. Data mining was based on 
gene ontology, gene set enrichment analysis (GSEA) and ingenuity pathway 
analysis (Mountain view, CA, USA) as described previously (11,12). Details 
are provided in supplementary methods. Integrative genomics was performed 
using publicly available gene expression datasets downloaded from GEO.
Results
Histopathological features of profiled tumours
The 20 cHCC-CC displayed the typical histopathological features 
described by N.D. Theise (4). All these tumours, recognized on 
hematoxylin-eosin staining, were classified in the cholangiolocellular 
carcinoma stem cell subtype (Figure  1A). Tumoural cells arranged 
in a tubular, cord-like, anastomosing pattern and were frequently 
embedded in a fibrous stroma. At the tumour periphery, the tumoural 
cords were continuous with the non-tumoural liver-cell cords in a 
replacing growth pattern. None of the tumours showed mucin forma-
tion. All cHCC-CC were positive for KRT19 and EpCAM, 75% of 
them being positive for ALB (Table I and Figure 1A–C). All three ICC 
corresponded to moderately differentiated adenocarcinomas and were 
strongly positive for KRT19 and EpCAM (Table I and Figure 1D–F). 
All seven HCC expressed ALB mRNA (Table I and Figure 1I).
cHCC-CC and CC exhibit overlapping gene expression profiles
Microarray experiments were performed to establish and to compare 
gene expression profiles of the 30 tumours described above and two 
normal liver samples harvested at the periphery of hepatic tumourec-
tomy specimens (untreated metastatic colon carcinoma). Based on the 
expression of the most variant genes, two main clusters were identified 
both by hierarchical clustering and multidimensional scaling analysis 
(Supplementary Figure 1). Cluster 1 included all normal liver samples 
and HCC, and cluster 2 included all CC and cHCC-CC. Thus, unsuper-
vised genome-wide expression profiling demonstrated that cHCC-CC 
tumours exhibited more similarity with CC than with HCC. Next, by 
using a supervised approach, which combined class  comparison and 
class prediction algorithms, we identified 1244 non-redundant genes dif-
ferentially expressed (P < 0.001, 2-fold change, FDR < 0.5%, 96–100% 
correct prediction) between HCC and cHCC-CC (Supplementary 
Figure  1B and Supplementary Table I). By hierarchical clustering 
analysis (Supplementary Figure 2), differentially expressed genes were 
further divided into a cHCC-CC gene set (i.e. 588 genes up-regulated in 
cHCC-CC) and a HCC gene set (i.e. 656 genes up-regulated in HCC). 
Validating the gene selection, HCC gene set included well-known HCC 
markers such as α-fetoprotein, glypican 3 or the non-coding H19 gene 
(Supplementary Figures 1B and 3D).
Down-regulated genes in cHCC-CC are linked to differentiated 
hepatocyte phenotype
Functional analysis of HCC and cHCC-CC gene sets was performed by 
using an unsupervised GSEA. This approach clearly demonstrated that 
gene signatures associated with hepatic metabolism were significantly 
(P < 0.05) enriched in the gene expression profiles of HCC compared 
with those of cHCC-CC (Figure 2A and Supplementary Figure 4A). 
Notably, numerous genes encoding plasma proteins (e.g. ALB) or those 
involved in glucose and lipid metabolism (e.g. G6PC), and detoxica-
tion (e.g. CYP2A6) were repressed in cHCC-CC (Supplementary 
Figure  3A). These results were further confirmed by gene ontology 
analysis (Supplementary Table II). Interestingly, down-regulated genes 
Table I. Clinicopathological features and in situ expression data of profiled tumours
Case Age Gender Etiologyb Fibrosisc Size(cm) β-catenin mutation EpCAM IHCd KRT19 IHC ALB ISHd
1 70 male GH 2  5 wt 1 1 2
2 62 male AC 3  4 wt 2 1 1
3 62 male AC 4  8 wt 1 1 2
4 50 male GH 4  2 wt 1 1 0
5 61 male AC 3  5 wt 2 1 2
6 69 male AC 3  7 wt 2 2 2
7 73 female None 0  3.5 wt 2 2 2
8 60 male GH 4  4 wt 2 1 1
9 35 female None 0 10 wt 2 1 0
cHCC-CCa 10 37 male None 2 11 wt 2 1 1
11 62 male None 0 14 wt 2 2 2
12 69 male AC 3  9 wt 2 1 2
13 57 female AC 4  8 wt 2 2 1
14 68 male AC 4  4 wt 2 1 0
15 58 male AC 4  5 wt 1 1 2
16 80 male AC 1  8 wt 1 1 1
17 59 female None 1 17 wt 1 1 0
18 54 male HCV 2  5 wt 2 1 2
19 56 female None 0  3 wt 2 1 1
20 69 female None 0  5 wt 2 1 0
1 73 male None 1  7 wt 2 1 0
CCa 2 53 male HBV 2  5 wt 2 2 0
3 61 female None 1 20 wt 1 1 2
1 67 male AC 3 10 wt 0 0 2
2 55 male AC 3 15 wt 0 0 1
3 39 male HBV 1 10 wt 0 0 2
HCCa 4 69 male AC 3  9 wt 0 0 2
5 74 male AC 4  7 wt 2 0 1
6 68 male HBV 4  6 wt 2 0 1
7 50 male AC 1 16 wt 2 0 2
acHCC-CC, combined hepatocholangiocarcinomas; CC, intrahepatic cholangiocarcinomas; HCC, hepatocellular carcinomas. 
bGH, genetic hemochromatosis; AC, alcohol consumption; HBV, hepatitis B virus; HCV, hepatitis C virus. 
cFibrosis was graded according to the METAVIR score. 
dEpCAM positivity was defined as membranous expression in ≥10% of tumour cells with moderate (1) or strong intensity (2), as well ALB ISH cytosolic 
positivity.
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in cHCC-CC were specifically associated with hepatocyte-enriched 
transcription factor HNF4A, as judged by GSEA (Figure 2A), inge-
nuity network analysis (Figure 2B) and promoter regulatory elements 
analysis (Supplementary Tables II and III). Accordingly, HNF4A itself 
was significantly repressed in cHCC-CC (Figure 2C). Altogether, these 
results demonstrated that genes related to mature hepatocyte differen-
tiation were down-regulated in cHCC-CC.
Up-regulated genes in cHCC-CC are associated with biliary com-
mitment and extracellular matrix remodelling
In agreement with our first observation that cHCC-CC and CC exhib-
ited similar expression profiles, analysing the cHCC-CC gene set 
highlighted signalling pathways typical of CC (i.e. biliary differen-
tiation and fibrosis). Notably, numerous fibrosis-associated genes, 
including potent pro-fibrotic factors (e.g. TGFβ, IL8), extracellular 
matrix (ECM) genes (e.g. COL1A1) and ECM-remodelling genes 
(e.g. MMP2, TIMP1) were up-regulated in cHCC-CC (Supplementary 
Figure 3E). These features were further validated by ingenuity path-
way analysis as illustrated by the analysis of enriched canonical path-
ways and gene networks (Figure 3A and 3B, respectively).
Unsupervised GSEA revealed that gene signatures of early 
liver development and stem cells were enriched in cHCC-CC 
(Supplementary Figure  4B) indicating that cHCC-CC exhib-
ited progenitor features. Interestingly, early biomarkers of biliary 
commitment (e.g. SOX9), as well as master genes of signalling 
pathways, which regulate the differentiation of hepatoblasts to chol-
angiocytes (e.g. TGFβ, Wnt, Notch), were induced in cHCC-CC 
(Supplementary Figure 3B). Enrichment of Wnt/β-catenin and TGFβ 
pathways in cHCC-CC was further validated by unsupervised GSEA 
(Supplementary Figure 4C). Corroborating this data, LEF1 transcrip-
tion factor was significantly increased in cHCC-CC (Figure 3C) and 
LEF1 binding sites occurred frequently in the promoter of cHCC-CC 
genes (Supplementary Table III). In addition, cHCC-CC exhibited a 
gene signature characteristic of the activation of the Wnt/β-catenin 
pathway in mouse hepatoblasts, which was associated with biliary 
ductal morphogenesis (13) (Supplementary Figure 4D). These obser-
vations suggested that a Wnt-mediated transcriptional program linked 
to cholangiocyte differentiation was present in cHCC-CC.
cHCC-CC signature in HCC with progenitor features and  
poor prognosis
Next, we compared our data with publicly available HCC datasets 
(11,14). By integrative genomics, we showed that cHCC-CC clustered 
with a specific HCC subset, which exhibited progenitor features, activa-
tion of TGFβ and poor prognosis (Cluster 1 in Figure 4A). Accordingly, 
TGFβ (11) and hepatoblast (14) signatures were significantly enriched 
in cHCC-CC (Figure 4B). Integration with another cohort of 98 HCC 
(15) further demonstrated that cHCC-CC recapitulated the previously 
Fig. 1. Microscopical pattern, EpCAM immunohistochemical staining and ALB mRNA expression in profiled tumours. (A–C) HES staining, expression of 
EpCAM by IHC and expression of ALB mRNA by in situ hybridization in cHCC-CC with features of cholangiolocellular carcinoma. (D–F) HES staining, 
expression of EpCAM by immunohistochemistry and expression of ALB mRNA by in situ hybridization in CC. (G–I) HES staining, expression of EpCAM by 
immunohistochemistry and expression of ALB mRNA by in situ hybridization in typical macrotrabecular HCC.
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described S1 HCC subtype, which was characterized by an aberrant 
Wnt and TGFβ activation along with a poor prognosis (Figure 4C–E). 
Further reinforcing the notion that cHCC-CC are associated with a 
bad prognosis, unsupervised GSEA demonstrated a specific enrich-
ment of genes linked to poor survival and recurrence in liver cancer 
(Supplementary Figure 4D). In addition, several markers of epithelial-
mesenchymal transition (EMT) and metastasis (e.g. SNAI2, VIM) 
were up-regulated in cHCC-CC as well as several genes that have 
been also proposed as cancer stem cell markers (e.g. EPCAM, CD133/
PROM1, CD44, THY1) (Supplementary Figure 3B,F).
Tissue microarray validation of hepatic progenitor features and 
Wnt/β-catenin activation in cHCC-CC
To validate our results, we analysed the in situ expression of markers 
of β-catenin activation together with markers of hepatocyte and 
cholangiocyte differentiation using tissue microarray, which included 
an independent set of 48 cHCC-CC, 54 CC and 152 HCC among 
them 60 (39%) displaying β-catenin mutation (Table II). As expected, 
HCC with mutant β-catenin displayed β-catenin nuclear positivity, 
expressed the hepatocyte β-catenin target GLUL (16) and were 
negative for EpCAM, in agreement with their well-differentiated 
phenotype (7). In contrast, cHCC-CC did not show β-catenin nuclear 
staining (30% displayed a faint cytosolic β-catenin staining) and 
Fig. 2. Absence of HNF4A-linked hepatocytic gene signature in cHCC-CC. 
(A) Unsupervised GSEA using cHCC-CC and HCC gene expression profiles 
(respectively on the left and right sides of each enrichment plot). Displayed 
are the enrichment plots for two gene signatures representative of liver-
specific genes and HNF4A-regulated genes. Hits (bar code) represent genes 
included in each signature. Enrichment scores are shown on the y-axis. The 
two signatures were shown to be significantly enriched in HCC and absent 
in cHCC-CC (P < 0.05). (B) Ingenuity analysis of HCC gene set (i.e. genes 
specifically down-regulated in cHCC-CC) highlighted a gene network 
centered on the liver-enriched HNF4A transcription factor. (C) HNF4A 
mRNA levels in normal livers (NL), hepatocellular carcinomas (HCC), 
cholangiocarcinomas (CC) and combined HCC-CC (cHCC-CC). HNF4A 
was significantly expressed at a lower level in CC and cHCC-CC. Statistical 
significance was evaluated using a two-sample unpaired Student’s t-test 
between HCC and cHCC-CC. *P < 0.001.
Table II. In situ expression of selected markers by IHC and ISH on TMA containing independent cHCC-CC, CC and HCC
β-catenin+ GLUL+ LEF1+ EpCAM+ SOX9+ KRT19+ ALB+
c-HCC-CC 
(n = 48)
0a
(0%)
0
(0%)
17
(35%)
47
(98%)
20
(47%)
48
(100%)
34
(77%)
CC 
(n = 54)
0a
(0%)
0
(0%)
18
(32%)
54
(100%)
25
(46%)
54
(100%)
18
(33%)
HCC
- with mutant 
 β-catenin (n = 60) 
- without mutant 
 β-catenin (n = 92)
38
(63%)
2
(2%)
54
(90%)
2
(2%)
7
(12%)
12
(13%)
4
(7%)
17
(18%)
0
(0%)
4
(6%)
4
(7%)
26
(28%)
60
(100%)
92
(100%)
Negative (0) β-catenin expression indicates that no nuclear staining was observed. EpCAM positivity was defined as membranous expression in ≥10% of tumour 
cells with moderate or strong intensity, as well ALB ISH positivity. For LEF1 and SOX9, tumours were considered as positive when the intensity of nuclear 
expression was greater than those observed in normal biliary cells.
aFaint positive cytosolic positivity alone in 30% of the cases.
Fig. 3. Signaling pathways associated with CC and biliary differentiation 
in cHCC-CC. (A) Ingenuity analysis of canonical pathways significantly 
enriched in cHCC-CC gene set (i.e. genes specifically up-regulated in 
cHCC-CC). Top-ranked pathways were associated with hepatic fibrosis, 
TGFβ and Wnt/β-catenin signaling. (B) Gene network analysis using 
cHCC-CC gene set. A specific network associated with TGFβ and 
extracellular matrix remodelling was identified. (C) Wnt/β-catenin associated 
LEF1 transcription factor was significantly expressed at a higher level in 
cHCC-CC and CC. Shown are LEF1 mRNA levels in normal livers (NL), 
hepatocellular carcinomas (HCC), cholangiocarcinomas (CC) and combined 
HCC-CC (cHCC-CC). Statistical significance of LEF1 mRNA abundance 
between HCC and cHCC-CC was evaluated using a two-sample unpaired 
Student’s t-test. *P < 0.001. (D) cHCC-CC exhibited a gene signature 
characteristic of the activation of the Wnt/β-catenin signaling in hepatoblast, 
which is associated with biliary cell fate. GSEA was performed using a gene 
set that signs APC invalidation in hepatoblast as described (13). Up- and 
down-regulated gene sets were found to be specifically enriched in cHCC-CC 
and HCC gene expression profiles, respectively (P < 0.05).
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showed a completely different spectrum of β-catenin target genes (all 
GLUL (-) and EpCAM (+) (17)) (Table II). As expected, expression 
of EpCAM and KRT19 hepatic progenitor markers was observed in 
>98% cHCC-CC. In agreement with the biliary differentiation trait, 
expression of LEF1 and SOX9 was similar in cHCC-CC and CC. ALB 
mRNA were detected in >75% cHCC-CC and >30% CC. Altogether, 
these observations corroborated the overlapping features between 
cHCC-CC and CC and supported the hypothesis that these tumours 
may arise from hepatic progenitor(s).
Discussion
cHCC-CC are aggressive and heterogeneous tumours, which exhibit 
both biliary and hepatocytic differentiation features. Their diagno-
sis can be difficult and relies on histopathological observations. The 
closed morphological pattern frequently observed between cHCC-CC 
and CC probably explains both the poor reproducibility of diagnosis 
among experts and the numerous terminologies employed for their 
characterization (18). Very few genomic studies (1) were designed to 
depict the molecular pathogenesis of these tumours. Here, we per-
formed a transcriptional analysis, which relies on a well-characterized 
series of cHCC-CC with stem cell features versus CC and typical 
macrotrabecular HCC. By unsupervised genome-wide expression 
profiling, we demonstrated that cHCC-CC clustered with CC rather 
than with HCC. This was confirmed by an altered hepatocytic dif-
ferentiation program, as underlined by the down-regulation of HNF4 
and its target genes.
By comparing our data with previously published HCC gene sig-
natures, we found that cHCC-CC recapitulated (i) HCC with the 
hepatoblast signature published by Lee et al. (14); (ii) the S1 HCC 
subgroup described by Hoshida et  al. (15); (iii) the G1-3 HCC 
groups from Boyault et  al. (19) (Supplementary Figure  5); and 
(iv) the EpCAM-positive HCC described by Yamashita et  al. (9) 
(data not shown). Strikingly, all these subgroups included poorly 
Fig. 4. cHCC-CC recapitulated HCC with a bad prognosis and hepatoblast features along with an aberrant activation of Wnt and TGFβ pathways. (A) Through 
an integrative genomic approach, cHCC-CC, HCC and CC gene expression profiles were merged with those derived from an independent cohort of 139 cases of 
human HCC (GSE1898 dataset from the GEO database). Integration was based on the expression of genes differentially expressed between HCC and cHCC-CC. 
Shown is the dendrogram overview of the integrated dataset where the identity of samples is displayed at the beginning of each row. Top, samples from the 
present study: HCC, hepatocellular carcinoma; CC, cholangiocarcinoma; cHCC-CC, combined HCC-CC. Bottom, HCC from the independent cohort that 
were previously assigned to specific subgroups with respect to cell origin (14) (HB, hepatoblast; HC, hepatocyte), prognosis (23) (A, bad prognosis; B, good, 
prognosis) and TGFβ signaling (11) (E, early; L, late TGFβ signature). Clustering analysis identified two major clusters. Cluster 1 included cHCC-CC and CC 
from the present study as well as HCC characterized by a poor prognosis and by the hepatoblast and late TGFβ signatures (subgroups A, HB and L, respectively) 
from the independent cohort. (B) GSEA validation of specific enrichment of TGBβ and liver cancer hepatoblast signatures in the gene expression profiles of 
cHCC-CC (P < 0.05). (C) Integration of cHCC-CC, HCC and CC gene profiles (the present study) with those derived from 98 human HCC (GSE10186 dataset 
from the GEO database). Those HCC were previously assigned to three robust subclasses characterized by an aberrant activation of the Wnt and TGFβ signaling 
pathways (S1), proliferation as well as MYC and AKT activation (S2), and hepatocyte differentiation (S3) (15). Clustering analysis of the integrated dataset 
identified two main clusters. Cluster 1 included 90–100% of cHCC-CC and CC from the present study as well as most of S1-type HCC from the independent 
cohort. Cluster 2 included all HCC from the present study and S3-type HCC. (D) Distribution of specific HCC subtypes from Hoshida’s classification (S1–3) 
between clusters C1 and C2 (P < 0.001). (E) Unsupervised gene set enrichment analysis confirmed the close association between cHCC-CC and HCC from 
subclass S1 defined in Hoshida’s study (P < 0.05) (15).
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differentiated tumours and were associated with a greater incidence 
of recurrence after surgical treatment and with stem cell/progenitor 
traits. Accordingly, it has recently been reported that scirrhous HCC, a 
rare variant of HCC, harbours cholangiocarcinoma traits with expres-
sion of EMT-related genes as in our cHCC-CC series, which also dis-
play an abundant stroma (20) supporting the idea of a continuous liver 
cancer spectrum between these tumours.
We also report that an activation of both TGFβ and Wnt/β-catenin 
cell signalling pathways is a prominent feature of cHCC-CC. TGFβ 
pathway is involved in biliary differentiation and in EMT. Accordingly, 
unsupervised GSEA demonstrated the up-regulation of EMT-related 
markers in cHCC-CC. Wnt/β-catenin pathway is also critical for bil-
iary/hepatocyte cellular commitment (13,21). We previously reported 
the important role of Wnt/β-catenin pathway in controlling the fate of 
hepatoblasts, preventing them from differentiating toward the hepato-
cyte lineage and guiding them to biliary ductal morphogenesis (13). 
Interestingly, we evidenced in cHCC-CC a particular Wnt/β-catenin 
signature that was not associated with β-catenin mutation. Although 
the mechanism of β-catenin activation remained to be identified in 
cHCC-CC, we hypothesize that a crosstalk with the TGFβ pathway 
may be involved based on previous observations by Hoshida et  al. 
(15) who reported a TGFβ-driven activation of β-catenin signalling in 
the S1 HCC subset, which clustered with our cHCC-CC series.
In an attempt to establish a discriminative fingerprint between 
cHCC-CC and CC, we observed in CC a higher expression of genes 
involved in the regulation of Wnt signalling (data not shown). This 
is consistent with the fine-tuning of Wnt activation necessary for the 
biliary commitment and further differentiation (22). Expression of 
such markers associated to ALB expression, which is more frequently 
observed in cHCC-CC than in CC, might distinguish these two enti-
ties. It remains an opened question that has to be strengthened by the 
analysis of larger series.
Whether hepatic primitive tumours arise from progenitor cells 
and/or from the dedifferentiation of neoplastically transformed 
mature hepatocytes is still a matter of debate. By demonstrating 
that cHCC-CC clustered both with CC and with a specific subset of 
HCC with progenitor features, our data support the former concept. 
Altogether, our data raise the hypothesis that ICC might derive from 
cHCC-CC originating from progenitor cells, with an ultimate induc-
tion of the CC phenotype.
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